Radiation and Environmental Biophysics

, Volume 50, Issue 1, pp 199–207

Boron neutron capture therapy (BNCT) for the treatment of liver metastases: biodistribution studies of boron compounds in an experimental model

  • Marcela A. Garabalino
  • Andrea Monti Hughes
  • Ana J. Molinari
  • Elisa M. Heber
  • Emiliano C. C. Pozzi
  • Jorge E. Cardoso
  • Lucas L. Colombo
  • Susana Nievas
  • David W. Nigg
  • Romina F. Aromando
  • Maria E. Itoiz
  • Verónica A. Trivillin
  • Amanda E. Schwint
Original Paper

DOI: 10.1007/s00411-010-0345-6

Cite this article as:
Garabalino, M.A., Monti Hughes, A., Molinari, A.J. et al. Radiat Environ Biophys (2011) 50: 199. doi:10.1007/s00411-010-0345-6

Abstract

We previously demonstrated the therapeutic efficacy of different boron neutron capture therapy (BNCT) protocols in an experimental model of oral cancer. BNCT is based on the selective accumulation of 10B carriers in a tumor followed by neutron irradiation. Within the context of exploring the potential therapeutic efficacy of BNCT for the treatment of liver metastases, the aim of the present study was to perform boron biodistribution studies in an experimental model of liver metastases in rats. Different boron compounds and administration conditions were assayed to determine which administration protocols would potentially be therapeutically useful in in vivo BNCT studies at the RA-3 nuclear reactor. A total of 70 BDIX rats were inoculated in the liver with syngeneic colon cancer cells DHD/K12/TRb to induce the development of subcapsular tumor nodules. Fourteen days post-inoculation, the animals were used for biodistribution studies. We evaluated a total of 11 administration protocols for the boron compounds boronophenylalanine (BPA) and GB-10 (Na210B10H10), alone or combined at different dose levels and employing different administration routes. Tumor, normal tissue, and blood samples were processed for boron measurement by atomic emission spectroscopy. Six protocols proved potentially useful for BNCT studies in terms of absolute boron concentration in tumor and preferential uptake of boron by tumor tissue. Boron concentration values in tumor and normal tissues in the liver metastases model show it would be feasible to reach therapeutic BNCT doses in tumor without exceeding radiotolerance in normal tissue at the thermal neutron facility at RA-3.

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Marcela A. Garabalino
    • 1
  • Andrea Monti Hughes
    • 1
  • Ana J. Molinari
    • 1
  • Elisa M. Heber
    • 1
  • Emiliano C. C. Pozzi
    • 1
    • 2
  • Jorge E. Cardoso
    • 3
  • Lucas L. Colombo
    • 3
  • Susana Nievas
    • 4
  • David W. Nigg
    • 5
  • Romina F. Aromando
    • 6
  • Maria E. Itoiz
    • 1
    • 6
  • Verónica A. Trivillin
    • 1
  • Amanda E. Schwint
    • 1
  1. 1.Department of RadiobiologyNational Atomic Energy CommissionSan Martin, Province Buenos AiresArgentina
  2. 2.Department of Research and Production ReactorsNational Atomic Energy CommissionEzeiza, Province Buenos AiresArgentina
  3. 3.Oncology Institute Angel H. RoffoCiudad Autónoma de Buenos AiresArgentina
  4. 4.Department of ChemistryNational Atomic Energy CommissionSan Martin, Province Buenos AiresArgentina
  5. 5.Idaho National LaboratoryIdaho FallsUSA
  6. 6.Department of Oral Pathology, Faculty of DentistryUniversity of Buenos AiresCiudad Autónoma de Buenos AiresArgentina